Live Webinar: Mar 3, 2021 9AM — 10 am (ET) / 3 pm — 4 pm (CET)

Calculating Risk and Return in Oncology Development Webinar

In this session, we investigate macro trends and forecasts in oncology using proprietary EvaluatePharma and Evaluate Omnium metrics, and offer perspectives from our work on the best frameworks and methodologies to quantify risk and return in highly dynamic oncology markets.

This live session will be animated by:

  • Dr. Paul Verdin, Head of Custom Solutions at Evaluate
  • Henry Barling, Senior Oncology Analyst at Evaluate

Register to this session

Your registration has been submitted.

You will shortly receive a confirmation in your mailbox.

Speakers

Dr. Paul Verdin

Head of Custom Solutions, Evaluate

Henry Barling

Senior Oncology Analyst, Evaluate

Speaker and Moderator Bios

Dr. Paul Verdin

Head of Custom Solutions, Evaluate

Dr. Paul Verdin is the Head of Custom Solutions at Evaluate with over 15 years of experience across research and consulting. Paul leads Evaluate’s Custom Solutions business incorporating all aspects of forecasting and valuation analysis, opportunity identification and quantification, and industry trend and outlook assessment. Paul has worked with a wide range of client organizations across therapy areas and across the pharma ecosystem from startup biotech companies seeking external perspectives into product strategy and positioning, to suppliers seeking insight into potential customer organizations, to large pharma Corporate Strategy groups providing insights directly to major pharma Executive teams. Paul has a PhD in Neuropharmacology.

Henry Barling

Senior Oncology Analyst, Evaluate

Henry Barling is a Senior Oncology Analyst within the Evaluate Custom Solutions team, having joined the team following the acquisition of Black Swan Analysis in April 2020. Henry has worked alongside various clients within the pharmaceutical industry on a wide range of projects including market forecasting, asset valuation and competitive intelligence primarily focussing in oncology. His role has allowed him to develop strong capabilities within patient based forecasting with a strong focus on dynamic patient flow modelling to capture key drivers of rapidly changing markets frequently seen within oncology. Alongside client projects Henry has also worked to develop oncology analysis frameworks and databases which have given him a broad knowledge of many cancer market landscapes.